Reduction of cardiovascular morbidity and mortality in Type 2 diabetes. A rational approach to hypoglycemic therapy

Journal of Endocrinological Investigation

Volumn 27, Issue 5, 2004, Pages 485-495

  Spallarossa, P ^a   Barsotti, A ^a   Cordera, R ^b   Ghigliotti, G ^a   Maggi, D ^a   Brunelli, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cardiovascular risk; Hyperglycemia; Insulin resistance; Insulin sensitizing agents; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; METFORMIN; PHENFORMIN; POTASSIUM CHANNEL; ROSIGLITAZONE; SULFONYLUREA; TOLBUTAMIDE;

ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG BINDING; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LACTIC ACIDOSIS; MEMBRANE POTENTIAL; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 3242717657     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345297     Document Type: Review

References (77)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 837-53.
2. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare profes-sionals from the American Heart Association. Circulation 1999, 100: 1134-46.
3. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with Type 2 diabetes. N Engl J Med 2003, 348: 383-93.
4. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyörälä K. Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects. Diabetologia 1993, 36: 1175-84.
5. Laakso M. Hyperglycemia and cardiovascular disease in Type 2 diabetes. Diabetes 1999, 48: 937-42.
6. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999, 22: 233-40.
7. Meinert CL, Knatterud GL,Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19: 789-830.
8. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352: 854-65.
9. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affaires Cooperative Study in Type II Diabetes. Diabetes Care 1995, 18: 1113-23.
10. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997, 157: 181-8.
11. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 2001, 24: 942-5.
12. Muggeo M, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of Type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000, 23: 45-50.
13. Brun E, Zoppini G, Zamboni C, Bonora E, Muggeo M. Glucose instability is associated with a high level of circulating p-selectin. Diabetes Care 2001, 24: 1685.
14. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence. Diabetologia 2001, 44: 2107-14.
15. Buse JB. Should postprandial glucose be routinely measured and treated to a particular target? No! Diabetes Care 2003, 26: 1615-8.
16. Muggeo M, Bolli G, Bompiani G, et al. Glycemic control and cardiovascular diseases in Type 2 diabetes mellitus. Beyond fasting glycemia and glycosylated hemoglobin. Diabetes Nutr Metab 2000, 13: 182-5.
17. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996, 39: 1577-83.
18. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria, Arch Intern Med 2001, 161: 397-405.
19. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW; Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002, 25: 1845-50.
20. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001, 24: 775-8.
21. Lebovitz HE. Effect of the postprandial state on nontraditional risk factors. Am J Cardiol 2001; 88: 20H-5H.
22. Inzucchi SE. Oral antihyperglycemic therapy for Type 2 diabetes: scientific review. JAMA 2002, 287: 360-72.
23. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 2000, 21: 220-9.
24. Garratt KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33: 119-24.
25. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in Type 2 diabetes. Diabetes Care 2002, 25: 2244-8.
26. Sturgess NC, Ashford ML, Cook DL, Hales CN. The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 1985, 2: 474-5.
27. Daut J, Maier-Rudolph W, von Beckerath N, Mehrke G, Gunther K, Goedel-Meinen L. Hypoxic dilation of coronary arteries is mediated by ATP-sensitive potassium channels. Science 1990, 247: 1341-4.
28. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991, 69: 571-81.
29. Bijlstra PJ, den Arend JA, Lutterman JA, Russel FG, Thien T, Smits P. Blockade of vascular ATP-sensitive potassium channels reduces the vasodilator response to ischaemia in humans. Diabetologia 1996, 39: 1562-8.
30. + channel blocker. Circulation 1994, 90: 700-5.
31. Bijlstra PJ, Lutterman JA, Russel FG, Thien T, Smits P. Interaction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humans. Diabetologia 1994, 39: 1083-90.
32. Klepzig H, Kober G, Matter C, et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 1999, 20: 439-46.
33. Posa I, Kocsis E, Nieszner E, Pogatsa G, Koltai MZ. Haemodynamic and metabolic effects of low daily dose sulphonylureas in diabetic dog hearts. Arzneimittelforschung 2002, 52: 552-9.
34. Spallarossa P, Schiavo M, Rossettin P, et al. Sulfonylurea treatment of Type 2 diabetic patients does not reduce the vasodilator response to ischemia. Diabetes Care 2001, 24: 738-42.
35. Scognamiglio R, Avogaro A, Vigili de Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischemia-induced myocardial dysfunction in Type 2 diabetes. Diabetes 2002, 51: 808-12.
36. American diabetes association policy statement: the UGDP controversy. Diabetes Care 1979, 2: 1-3.
37. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003, 46: 875-91.
38. Caulfield MT, O'Brien KD. Cardiovascular safety of oral antidiabetic agents: the insulin secretagogues. Clin Diabetes 2002, 20: 81-4.
39. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979, 2: 154-60.
40. Spallarossa P, Cordera R, Andraghetti G, Bertero G, Brunelli C, Caponnetto S. Association between plasma insulin and angiographically documented significant coronary artery disease. Am J Cardiol 1994, 74: 177-9.
41. Stout RW. Insulin and atheroma-an update. Lancet 1987, 1: 1077-9.
42. Nordt TK, Sawa H, Fujii S, Sobel BE. Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo. Circulation 1995, 91: 764-70.
43. Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002, 105: 576-82.
44. Chen YL, Messina EJ. Dilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol 1996, 270(Pt 2): H2120-4.
45. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001, 86: 3257-65.
46. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000, 106: 453-8.
47. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998, 97: 1695-701.
48. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002, 113: 308-16.
49. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26: 57-65.
50. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345: 1359-67.
51. Iwakura K, Ito H, Ikushima M, Kawano S, et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003, 41: 1-7.
52. Verma S, Maitland A, Weisel RD, et al. Increased endothelin-1 production in diabetic patients after cardioplegic arrest and reperfusion impairs coronary vascular reactivity: reversal by means of endothelin antagonism. J Thorac Cardiovasc Surg 2002, 123: 1114-9.
53. Vetter NJ, Strange RC, Adams W, Oliver MF. Initial metabolic and hormonal response to acute myocardial infarction. Lancet 1974, 1: 284-8.
54. Rackley CE, Russell RO Jr, Rogers WJ, Mantle JA, McDaniel HG, Papapietro SE. Clinical experience with glucose-insulin-potassium therapy in acute myocardial infarction. Am Heart J 1981, 102: 1038-49.
55. Zierler KL. Possible mechanisms of insulin action on membrane potential and ion fluxes. Am J Med 1966, 40: 735-9.
56. Nygren J, Carlsson-Skwirut C, Brismar K, Thorell A, Ljungqvist O, Bang P. Insulin infusion increases levels of free IGF-I and IGFBP-3 proteolytic activity in patients after surgery. Am J Physiol Endocrinol Metab 2001, 281: E736-41.
57. Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-I and angiographically documented coronary artery disease. Am J Cardiol 1996, 77: 200-2.
58. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990, 263: 2893-8.
59. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105: 311-20.
60. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002, 137: 25-33.
61. Mithieux G, Guignot L, Bordet JC, Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002, 5: 139-43.
62. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996, 334: 574-9.
63. Wu MS, Johnston P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990, 13: 1-8.
64. Grant PJ, Stickland MH, Booth NA, Prentice CR. Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in Type 2 diabetic patients. Diabet Med 1991, 8: 361-5.
65. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in Type 2 diabetes mellitus (Cochrane Review). Cochrane Database Syst Rev 2003, (2): CD002967.
66. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003, 326: 4-5.
67. Furnsinn C, Waldhausl W. Thiazolidinediones: metabolic actions in vitro. Diabetologia 2002, 45: 1211-23.
68. Sunayama S, Watanabe Y, Daida H, Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000, 11: 397-402.
69. Hsueh WA, Law RE. PPARgamma and atherosclerosis: effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001, 21: 1891-5.
70. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003, 24: 278-301.
71. Ross R. Atherosclerosis: an inflammatory disease. Lancet 1999, 340: 115-26.
72. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22: 717-26.
73. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with Type 2 diabetes. Diabetes Care 2002, 25: 542-9.
74. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 2002, 106: 679-84.
75. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Inhibitory effect of pioglitazone on carotid arterial wall thickness in Type 2 diabetes. J Clin Endocrinol Metab 2001, 86: 3452-6.
76. Murakami T, Mizuno S, Ohsato K, et al. Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 1999, 84: 92-4.
77. Takagi T, Yammamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with Type 2 diabetes mellitus. Am J Cardiol 2002, 89: 318-22.